Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Library Location
Language
Publication Date1998, Lung biology in health and disease, ISBN 9780824701673, Volume 120., xviii, 493
Five-Lipoxygenase Products in Asthma offers an authoritative examination of the biochemistry, basic pharmacology, and clinical pharmacology of the leukotrienes...
Chemotherapy | Pathophysiology | Metabolism | Leukotrienes | Asthma
Chemotherapy | Pathophysiology | Metabolism | Leukotrienes | Asthma
Book
Details 
Medicinal Research Reviews, ISSN 0198-6325, 01/2013, Volume 33, Issue 1, pp. 139 - 189
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to...
antioxidant drugs | CDK5 inhibitors | anti‐inflammatory drugs | AChE peripheral anionic site | CK‐1 inhibitors | ERK2‐inhibitors | Ca2+ dyshomeostasis | BACE‐1 inhibitors | amyloid–β antiaggregating agents | NSAIDs | neuroprotection | multitarget drugs | GSK‐3β inhibitors | dual AChE inhibitors | metal chelators | Alzheimer's disease | Ca2+ overload | oxidative stress | multiactive compounds | 1,4‐dihydropyridines | voltage‐dependent calcium channels | Neuroprotection | Oxidative stress | Dual AChE inhibitors | Anti-inflammatory drugs | GSK-3β inhibitors | Antioxidant drugs | overload | Metal chelators | Multitarget drugs | Voltage-dependent calcium channels | CK-1 inhibitors | BACE-1 inhibitors | dyshomeostasis | 1,4-dihydropyridines | ERK2-inhibitors | Multiactive compounds | Amyloid-β antiaggregating agents | GSK-3 ss inhibitors | anti-inflammatory drugs | voltage-dependent calcium channels | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | POTENT ACETYLCHOLINESTERASE INHIBITORS | amyloid-ss antiaggregating agents | M1 MUSCARINIC AGONISTS | CHEMISTRY, MEDICINAL | AMYLOID PRECURSOR PROTEIN | MOLECULAR MODELING INVESTIGATIONS | HERPES-SIMPLEX-VIRUS | TACRINE-DIHYDROPYRIDINE HYBRIDS | PERIPHERAL ANIONIC SITE | NMDA RECEPTOR ANTAGONIST | Calcium Channels - metabolism | Humans | Enzyme Inhibitors - pharmacology | Alzheimer Disease - drug therapy | tau Proteins - metabolism | Receptors, N-Methyl-D-Aspartate | Alzheimer Disease - enzymology | Enzyme Inhibitors - therapeutic use | Disease Progression | Alzheimer Disease - pathology | Amyloid Precursor Protein Secretases - metabolism | Butyrylcholinesterase - metabolism | Amyloid beta-Peptides - metabolism | Ligands | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Binding Sites | Acetylcholinesterase - metabolism | Care and treatment | Calcium channels | Glycogen | Development and progression | Glutamate | Target marketing | Antioxidants | Methyl aspartate | Enzyme inhibitors | Synthesis | Surface active agents | Drug therapy | Cancer
antioxidant drugs | CDK5 inhibitors | anti‐inflammatory drugs | AChE peripheral anionic site | CK‐1 inhibitors | ERK2‐inhibitors | Ca2+ dyshomeostasis | BACE‐1 inhibitors | amyloid–β antiaggregating agents | NSAIDs | neuroprotection | multitarget drugs | GSK‐3β inhibitors | dual AChE inhibitors | metal chelators | Alzheimer's disease | Ca2+ overload | oxidative stress | multiactive compounds | 1,4‐dihydropyridines | voltage‐dependent calcium channels | Neuroprotection | Oxidative stress | Dual AChE inhibitors | Anti-inflammatory drugs | GSK-3β inhibitors | Antioxidant drugs | overload | Metal chelators | Multitarget drugs | Voltage-dependent calcium channels | CK-1 inhibitors | BACE-1 inhibitors | dyshomeostasis | 1,4-dihydropyridines | ERK2-inhibitors | Multiactive compounds | Amyloid-β antiaggregating agents | GSK-3 ss inhibitors | anti-inflammatory drugs | voltage-dependent calcium channels | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | POTENT ACETYLCHOLINESTERASE INHIBITORS | amyloid-ss antiaggregating agents | M1 MUSCARINIC AGONISTS | CHEMISTRY, MEDICINAL | AMYLOID PRECURSOR PROTEIN | MOLECULAR MODELING INVESTIGATIONS | HERPES-SIMPLEX-VIRUS | TACRINE-DIHYDROPYRIDINE HYBRIDS | PERIPHERAL ANIONIC SITE | NMDA RECEPTOR ANTAGONIST | Calcium Channels - metabolism | Humans | Enzyme Inhibitors - pharmacology | Alzheimer Disease - drug therapy | tau Proteins - metabolism | Receptors, N-Methyl-D-Aspartate | Alzheimer Disease - enzymology | Enzyme Inhibitors - therapeutic use | Disease Progression | Alzheimer Disease - pathology | Amyloid Precursor Protein Secretases - metabolism | Butyrylcholinesterase - metabolism | Amyloid beta-Peptides - metabolism | Ligands | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Binding Sites | Acetylcholinesterase - metabolism | Care and treatment | Calcium channels | Glycogen | Development and progression | Glutamate | Target marketing | Antioxidants | Methyl aspartate | Enzyme inhibitors | Synthesis | Surface active agents | Drug therapy | Cancer
Journal Article
Details
Digital rights
Loading RightsExpert Opinion on Investigational Drugs, ISSN 1354-3784, 06/2017, Volume 26, Issue 6, pp. 699 - 711
Introduction: Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of malignant plasma cells. patient outcome has improved markedly...
PIM-Kinase inhibitor | proteasome inhibitor | CDK inhibitor | AKT inhibitor | Multiple myeloma | single-agent | alkylator | kinesin-spindle protein inhibitor | MEK inhibitor | monoclonal antibody | BCL-2 inhibitor | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | DOSE-ESCALATION | IN-VITRO | WORKING GROUP | UNFOLDED PROTEIN RESPONSE | PHARMACOLOGY & PHARMACY | PLASMA-CELL LEUKEMIA | PHASE-I | PROTEASOME INHIBITORS | Drugs, Investigational - pharmacology | Proteasome Inhibitors - pharmacology | Antibodies, Monoclonal - pharmacology | Humans | Proteasome Inhibitors - administration & dosage | Drugs, Investigational - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Proteasome Inhibitors - therapeutic use | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | Antibodies, Monoclonal - administration & dosage | Drug Design | Drugs, Investigational - administration & dosage | Antineoplastic Agents - pharmacology
PIM-Kinase inhibitor | proteasome inhibitor | CDK inhibitor | AKT inhibitor | Multiple myeloma | single-agent | alkylator | kinesin-spindle protein inhibitor | MEK inhibitor | monoclonal antibody | BCL-2 inhibitor | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | DOSE-ESCALATION | IN-VITRO | WORKING GROUP | UNFOLDED PROTEIN RESPONSE | PHARMACOLOGY & PHARMACY | PLASMA-CELL LEUKEMIA | PHASE-I | PROTEASOME INHIBITORS | Drugs, Investigational - pharmacology | Proteasome Inhibitors - pharmacology | Antibodies, Monoclonal - pharmacology | Humans | Proteasome Inhibitors - administration & dosage | Drugs, Investigational - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Proteasome Inhibitors - therapeutic use | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | Antibodies, Monoclonal - administration & dosage | Drug Design | Drugs, Investigational - administration & dosage | Antineoplastic Agents - pharmacology
Journal Article
Details
Digital rights
Loading RightsExpert Opinion on Drug Discovery, ISSN 1746-0441, 09/2013, Volume 8, Issue 9, pp. 1095 - 1116
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) have been on the increase during the past decade, due to the steady growth of the elderly and...
acyl t-RNA synthase inhibitor | Clp protease inhibitor | methicillin-resistant Staphylococcus aureus | two-component system inhibitor | elongation factor G inhibitor | linezolid | antibacterial agents | combination therapy | daptomycin | vancomycin | β-lactamase inhibitor | antibacterial vaccine | dihydropteroate synthase inhibitor | peptidoglycan biosynthesis inhibitor | Pol IIIC inhibitor | electron transport inhibitor | RNA-polymerase inhibitor | phage therapy | peptide deformylase inhibitor | menaquinone biosynthesis inhibitor | Gram-positive pathogens | antibiotics | antimicrobial peptides | dihydrofolate reductase inhibitor | FAS II inhibitor | Linezolid | Peptide deformylase inhibitor | Daptomycin | Dihydropteroate synthase inhibitor | Vancomycin | Combination therapy | Antimicrobial peptides | Menaquinone biosynthesis inhibitor | Antibacterial vaccine | Dihydrofolate reductase inhibitor | Acyl t-RNA synthase inhibitor | Elongation factor G inhibitor | Antibacterial agents | Electron transport inhibitor | Peptidoglycan biosynthesis inhibitor | Antibiotics | Methicillin-resistant Staphylococcus aureus | Phage therapy | Two-component system inhibitor | SOFT-TISSUE INFECTIONS | INTENSIVE-CARE UNITS | beta-lactamase inhibitor | RESISTANT STAPHYLOCOCCUS-AUREUS | PHARMACOLOGY & PHARMACY | IN-VITRO ACTIVITY | TOREZOLID PHOSPHATE TR-701 | BRIDGED BICYCLIC MACROLIDE | DIHYDROFOLATE-REDUCTASE INHIBITOR | QUALITY-CONTROL RANGES | Anti-Bacterial Agents - therapeutic use | Animals | Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Humans | Drug Discovery | Methicillin-Resistant Staphylococcus aureus | elongation factor G (EF-G) inhibitor | peptide deformylase (PDF) inhibitor | methicillin-resistant Staphylococcus aureus (MRSA) | PolIIC inhibitor | β5 -lactamase inhibitor
acyl t-RNA synthase inhibitor | Clp protease inhibitor | methicillin-resistant Staphylococcus aureus | two-component system inhibitor | elongation factor G inhibitor | linezolid | antibacterial agents | combination therapy | daptomycin | vancomycin | β-lactamase inhibitor | antibacterial vaccine | dihydropteroate synthase inhibitor | peptidoglycan biosynthesis inhibitor | Pol IIIC inhibitor | electron transport inhibitor | RNA-polymerase inhibitor | phage therapy | peptide deformylase inhibitor | menaquinone biosynthesis inhibitor | Gram-positive pathogens | antibiotics | antimicrobial peptides | dihydrofolate reductase inhibitor | FAS II inhibitor | Linezolid | Peptide deformylase inhibitor | Daptomycin | Dihydropteroate synthase inhibitor | Vancomycin | Combination therapy | Antimicrobial peptides | Menaquinone biosynthesis inhibitor | Antibacterial vaccine | Dihydrofolate reductase inhibitor | Acyl t-RNA synthase inhibitor | Elongation factor G inhibitor | Antibacterial agents | Electron transport inhibitor | Peptidoglycan biosynthesis inhibitor | Antibiotics | Methicillin-resistant Staphylococcus aureus | Phage therapy | Two-component system inhibitor | SOFT-TISSUE INFECTIONS | INTENSIVE-CARE UNITS | beta-lactamase inhibitor | RESISTANT STAPHYLOCOCCUS-AUREUS | PHARMACOLOGY & PHARMACY | IN-VITRO ACTIVITY | TOREZOLID PHOSPHATE TR-701 | BRIDGED BICYCLIC MACROLIDE | DIHYDROFOLATE-REDUCTASE INHIBITOR | QUALITY-CONTROL RANGES | Anti-Bacterial Agents - therapeutic use | Animals | Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Humans | Drug Discovery | Methicillin-Resistant Staphylococcus aureus | elongation factor G (EF-G) inhibitor | peptide deformylase (PDF) inhibitor | methicillin-resistant Staphylococcus aureus (MRSA) | PolIIC inhibitor | β5 -lactamase inhibitor
Journal Article
Details
Digital rights
Loading RightsNature Reviews Cancer, ISSN 1474-175X, 01/2017, Volume 17, Issue 2, pp. 93 - 115
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant activity of various cell cycle proteins. Therefore, cell cycle...
INVESTIGATIONAL AURORA KINASE | PHASE-II TRIAL | POLO-LIKE-KINASE | EARLY EMBRYONIC-DEVELOPMENT | DINACICLIB SCH 727965 | ADVANCED SOLID TUMORS | ONCOLOGY | PREVENTS TUMOR-GROWTH | VOLASERTIB BI 6727 | DEPENDENT KINASE INHIBITOR | SMALL-MOLECULE INHIBITOR | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Humans | Checkpoint Kinase 1 - physiology | Aurora Kinase A - antagonists & inhibitors | Cyclin-Dependent Kinase 2 - physiology | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - physiology | Aurora Kinase A - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Protein-Serine-Threonine Kinases - physiology | Checkpoint Kinase 1 - antagonists & inhibitors | Clinical Trials as Topic | Neoplasms - drug therapy | Animals | Cyclin-Dependent Kinase 4 - physiology | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - physiology | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - physiology | Nuclear Proteins - physiology | Cell Cycle Proteins - physiology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Care and treatment | Usage | MicroRNA | Cell cycle | Research | Cancer
INVESTIGATIONAL AURORA KINASE | PHASE-II TRIAL | POLO-LIKE-KINASE | EARLY EMBRYONIC-DEVELOPMENT | DINACICLIB SCH 727965 | ADVANCED SOLID TUMORS | ONCOLOGY | PREVENTS TUMOR-GROWTH | VOLASERTIB BI 6727 | DEPENDENT KINASE INHIBITOR | SMALL-MOLECULE INHIBITOR | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Humans | Checkpoint Kinase 1 - physiology | Aurora Kinase A - antagonists & inhibitors | Cyclin-Dependent Kinase 2 - physiology | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - physiology | Aurora Kinase A - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Protein-Serine-Threonine Kinases - physiology | Checkpoint Kinase 1 - antagonists & inhibitors | Clinical Trials as Topic | Neoplasms - drug therapy | Animals | Cyclin-Dependent Kinase 4 - physiology | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - physiology | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - physiology | Nuclear Proteins - physiology | Cell Cycle Proteins - physiology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Care and treatment | Usage | MicroRNA | Cell cycle | Research | Cancer
Journal Article
Details
Digital rights
Loading RightsJournal of Medicinal Chemistry, ISSN 0022-2623, 02/2016, Volume 59, Issue 4, pp. 1271 - 1298
Bromodomains, small protein modules that recognize acetylated lysine on histones, play a significant role in the epigenome, where they function as “readers”...
CHEMISTRY, MEDICINAL | SWI/SNF COMPLEXES | SMALL-MOLECULE INHIBITORS | PROSTATE-CANCER | SELECTIVE INHIBITORS | GENE-EXPRESSION | CHEMICAL PROBE | TUMOR-SUPPRESSOR | BET INHIBITORS | HISTONE ACETYLTRANSFERASE | PHD FINGER | Small Molecule Libraries - pharmacology | Antigens, Nuclear - metabolism | Humans | Drug Discovery - methods | CREB-Binding Protein - antagonists & inhibitors | Chromosomal Proteins, Non-Histone - antagonists & inhibitors | DNA-Binding Proteins - metabolism | CREB-Binding Protein - metabolism | Protein Processing, Post-Translational - drug effects | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Lysine - metabolism | Protein-Serine-Threonine Kinases - metabolism | RNA-Binding Proteins - antagonists & inhibitors | Nerve Tissue Proteins - antagonists & inhibitors | ATPases Associated with Diverse Cellular Activities | DNA-Binding Proteins - antagonists & inhibitors | Chromosomal Proteins, Non-Histone - metabolism | Carrier Proteins - antagonists & inhibitors | Adenosine Triphosphatases - metabolism | Models, Molecular | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Nerve Tissue Proteins - metabolism | Transcription Factors - metabolism | Adenosine Triphosphatases - antagonists & inhibitors | DNA Helicases - metabolism | Small Molecule Libraries - chemistry | Acetylation - drug effects | Animals | Carrier Proteins - metabolism | Nuclear Proteins - antagonists & inhibitors | DNA Helicases - antagonists & inhibitors | Histones - metabolism | Adaptor Proteins, Signal Transducing - metabolism | RNA-Binding Proteins - metabolism
CHEMISTRY, MEDICINAL | SWI/SNF COMPLEXES | SMALL-MOLECULE INHIBITORS | PROSTATE-CANCER | SELECTIVE INHIBITORS | GENE-EXPRESSION | CHEMICAL PROBE | TUMOR-SUPPRESSOR | BET INHIBITORS | HISTONE ACETYLTRANSFERASE | PHD FINGER | Small Molecule Libraries - pharmacology | Antigens, Nuclear - metabolism | Humans | Drug Discovery - methods | CREB-Binding Protein - antagonists & inhibitors | Chromosomal Proteins, Non-Histone - antagonists & inhibitors | DNA-Binding Proteins - metabolism | CREB-Binding Protein - metabolism | Protein Processing, Post-Translational - drug effects | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Lysine - metabolism | Protein-Serine-Threonine Kinases - metabolism | RNA-Binding Proteins - antagonists & inhibitors | Nerve Tissue Proteins - antagonists & inhibitors | ATPases Associated with Diverse Cellular Activities | DNA-Binding Proteins - antagonists & inhibitors | Chromosomal Proteins, Non-Histone - metabolism | Carrier Proteins - antagonists & inhibitors | Adenosine Triphosphatases - metabolism | Models, Molecular | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Nerve Tissue Proteins - metabolism | Transcription Factors - metabolism | Adenosine Triphosphatases - antagonists & inhibitors | DNA Helicases - metabolism | Small Molecule Libraries - chemistry | Acetylation - drug effects | Animals | Carrier Proteins - metabolism | Nuclear Proteins - antagonists & inhibitors | DNA Helicases - antagonists & inhibitors | Histones - metabolism | Adaptor Proteins, Signal Transducing - metabolism | RNA-Binding Proteins - metabolism
Journal Article
Details
Digital rights
Loading RightsThe Journal of Immunology, ISSN 0022-1767, 01/2004, Volume 172, Issue 1, pp. 567 - 576
The signaling mechanism by which the anti-inflammatory cytokine IL-10 mediates suppression of proinflammatory cytokine synthesis remains largely unknown....
RHEUMATOID-ARTHRITIS | TUMOR-NECROSIS-FACTOR | DNA-BINDING | HUMAN NEUTROPHILS | TYROSINE PHOSPHORYLATION | INTERLEUKIN-10 RECEPTOR | GENE-EXPRESSION | KAPPA-B-ALPHA | IMMUNOLOGY | HUMAN MONOCYTES | MONONUCLEAR PHAGOCYTES | Protein Binding - genetics | Protein Biosynthesis | Interleukin-6 - antagonists & inhibitors | Humans | Tumor Necrosis Factor-alpha - genetics | Immunoglobulins - genetics | Lipopolysaccharides - antagonists & inhibitors | RNA, Messenger - metabolism | Suppressor of Cytokine Signaling Proteins | Repressor Proteins - antagonists & inhibitors | Antigens, CD - metabolism | Trans-Activators - physiology | Protein Tyrosine Phosphatases - antagonists & inhibitors | RNA, Messenger - biosynthesis | Protein Tyrosine Phosphatases - genetics | Inflammation Mediators - physiology | Glycoproteins - genetics | DNA-Binding Proteins - physiology | Protein Tyrosine Phosphatases - biosynthesis | DNA-Binding Proteins - antagonists & inhibitors | Signal Transduction - genetics | DNA - metabolism | Down-Regulation - genetics | Macrophages - metabolism | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | Repressor Proteins - biosynthesis | Up-Regulation - immunology | Interleukin-10 - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Adenoviruses, Human - genetics | Interleukin-10 - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Phosphorylation | Tissue Inhibitor of Metalloproteinase-1 - biosynthesis | Antigens, CD - biosynthesis | Receptors, Cell Surface | Receptors, IgG - biosynthesis | Receptors, IgG - antagonists & inhibitors | Interleukin-10 - physiology | Signal Transduction - immunology | Tissue Inhibitor of Metalloproteinase-1 - metabolism | Signaling Lymphocytic Activation Molecule Family Member 1 | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | RNA, Messenger - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | Trans-Activators - genetics | Inflammation Mediators - antagonists & inhibitors | Trans-Activators - biosynthesis | Immunoglobulins - biosynthesis | Macrophages - immunology | Inflammation Mediators - immunology | Receptors, Tumor Necrosis Factor - metabolism | Immune Sera - pharmacology | Proteins - physiology | Cells, Cultured | Glycoproteins - antagonists & inhibitors | Histocompatibility Antigens Class II - biosynthesis | Tissue Inhibitor of Metalloproteinase-1 - antagonists & inhibitors | Transcription Factors - antagonists & inhibitors | Transcription Factors - biosynthesis | Up-Regulation - genetics | DNA-Binding Proteins - genetics | DNA - antagonists & inhibitors | Glycoproteins - biosynthesis | Suppressor of Cytokine Signaling 3 Protein | Down-Regulation - immunology | Interleukin-6 - biosynthesis | Receptors, Tumor Necrosis Factor - biosynthesis | STAT3 Transcription Factor | Trans-Activators - antagonists & inhibitors | Genetic Vectors | DNA-Binding Proteins - biosynthesis | Tumor Necrosis Factor-alpha - antagonists & inhibitors
RHEUMATOID-ARTHRITIS | TUMOR-NECROSIS-FACTOR | DNA-BINDING | HUMAN NEUTROPHILS | TYROSINE PHOSPHORYLATION | INTERLEUKIN-10 RECEPTOR | GENE-EXPRESSION | KAPPA-B-ALPHA | IMMUNOLOGY | HUMAN MONOCYTES | MONONUCLEAR PHAGOCYTES | Protein Binding - genetics | Protein Biosynthesis | Interleukin-6 - antagonists & inhibitors | Humans | Tumor Necrosis Factor-alpha - genetics | Immunoglobulins - genetics | Lipopolysaccharides - antagonists & inhibitors | RNA, Messenger - metabolism | Suppressor of Cytokine Signaling Proteins | Repressor Proteins - antagonists & inhibitors | Antigens, CD - metabolism | Trans-Activators - physiology | Protein Tyrosine Phosphatases - antagonists & inhibitors | RNA, Messenger - biosynthesis | Protein Tyrosine Phosphatases - genetics | Inflammation Mediators - physiology | Glycoproteins - genetics | DNA-Binding Proteins - physiology | Protein Tyrosine Phosphatases - biosynthesis | DNA-Binding Proteins - antagonists & inhibitors | Signal Transduction - genetics | DNA - metabolism | Down-Regulation - genetics | Macrophages - metabolism | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | Repressor Proteins - biosynthesis | Up-Regulation - immunology | Interleukin-10 - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Adenoviruses, Human - genetics | Interleukin-10 - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Phosphorylation | Tissue Inhibitor of Metalloproteinase-1 - biosynthesis | Antigens, CD - biosynthesis | Receptors, Cell Surface | Receptors, IgG - biosynthesis | Receptors, IgG - antagonists & inhibitors | Interleukin-10 - physiology | Signal Transduction - immunology | Tissue Inhibitor of Metalloproteinase-1 - metabolism | Signaling Lymphocytic Activation Molecule Family Member 1 | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | RNA, Messenger - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | Trans-Activators - genetics | Inflammation Mediators - antagonists & inhibitors | Trans-Activators - biosynthesis | Immunoglobulins - biosynthesis | Macrophages - immunology | Inflammation Mediators - immunology | Receptors, Tumor Necrosis Factor - metabolism | Immune Sera - pharmacology | Proteins - physiology | Cells, Cultured | Glycoproteins - antagonists & inhibitors | Histocompatibility Antigens Class II - biosynthesis | Tissue Inhibitor of Metalloproteinase-1 - antagonists & inhibitors | Transcription Factors - antagonists & inhibitors | Transcription Factors - biosynthesis | Up-Regulation - genetics | DNA-Binding Proteins - genetics | DNA - antagonists & inhibitors | Glycoproteins - biosynthesis | Suppressor of Cytokine Signaling 3 Protein | Down-Regulation - immunology | Interleukin-6 - biosynthesis | Receptors, Tumor Necrosis Factor - biosynthesis | STAT3 Transcription Factor | Trans-Activators - antagonists & inhibitors | Genetic Vectors | DNA-Binding Proteins - biosynthesis | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Details
Digital rights
Loading Rights2002, Current topics in microbiology and immunology, ISBN 3540430962, Volume 268., 213
Book
Details
Genes and Development, ISSN 0890-9369, 05/2013, Volume 27, Issue 10, pp. 1101 - 1114
Tumorigenesis results from dysregulation of oncogenes and tumor suppressors that influence cellular proliferation, differentiation, apoptosis, and/or...
Huwe1 | c-Myc | Mule | Ras | p21 | Miz1 | DNA-DAMAGE | KERATINOCYTE GROWTH | DEVELOPMENTAL BIOLOGY | CELL BIOLOGY | BASE EXCISION-REPAIR | HUWE1 UBIQUITIN LIGASE | NEGATIVE REGULATION | GENETICS & HEREDITY | ARF TUMOR-SUPPRESSOR | DIFFERENTIATION | MIZ-1 | HUMAN CANCER | Protein Inhibitors of Activated STAT - deficiency | Tetradecanoylphorbol Acetate - pharmacology | 9,10-Dimethyl-1,2-benzanthracene - pharmacology | Male | Protein Inhibitors of Activated STAT - metabolism | Cyclin-Dependent Kinase Inhibitor p15 - biosynthesis | Oncogene Protein p21(ras) - metabolism | Cyclin-Dependent Kinase Inhibitor p16 | Oncogene Protein p21(ras) - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Cell Transformation, Neoplastic - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | Nuclear Proteins - deficiency | Protein Inhibitors of Activated STAT - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Nuclear Proteins - genetics | Protein Inhibitors of Activated STAT - antagonists & inhibitors | Skin Neoplasms - pathology | Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis | Signal Transduction | Down-Regulation | Cells, Cultured | Ubiquitin-Protein Ligases - metabolism | Nuclear Proteins - metabolism | Skin Neoplasms - chemically induced | Proto-Oncogene Proteins c-myc - metabolism | Mice, Knockout | Skin Neoplasms - metabolism | Keratinocytes - pathology | Animals | Tumor Suppressor Protein p53 | Keratinocytes - drug effects | Keratinocytes - metabolism | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-myc - deficiency | Skin Neoplasms - genetics | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Ubiquitin-Protein Ligases - deficiency | Mice | Proto-Oncogene Proteins c-myc - genetics | Cyclin-Dependent Kinase Inhibitor p15 - metabolism | Genes, ras | Ubiquitin-Protein Ligases - genetics | Oncogene Protein p21(ras) - genetics | Carcinogenesis | Ras genes | Analysis | Research Paper
Huwe1 | c-Myc | Mule | Ras | p21 | Miz1 | DNA-DAMAGE | KERATINOCYTE GROWTH | DEVELOPMENTAL BIOLOGY | CELL BIOLOGY | BASE EXCISION-REPAIR | HUWE1 UBIQUITIN LIGASE | NEGATIVE REGULATION | GENETICS & HEREDITY | ARF TUMOR-SUPPRESSOR | DIFFERENTIATION | MIZ-1 | HUMAN CANCER | Protein Inhibitors of Activated STAT - deficiency | Tetradecanoylphorbol Acetate - pharmacology | 9,10-Dimethyl-1,2-benzanthracene - pharmacology | Male | Protein Inhibitors of Activated STAT - metabolism | Cyclin-Dependent Kinase Inhibitor p15 - biosynthesis | Oncogene Protein p21(ras) - metabolism | Cyclin-Dependent Kinase Inhibitor p16 | Oncogene Protein p21(ras) - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Cell Transformation, Neoplastic - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | Nuclear Proteins - deficiency | Protein Inhibitors of Activated STAT - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Nuclear Proteins - genetics | Protein Inhibitors of Activated STAT - antagonists & inhibitors | Skin Neoplasms - pathology | Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis | Signal Transduction | Down-Regulation | Cells, Cultured | Ubiquitin-Protein Ligases - metabolism | Nuclear Proteins - metabolism | Skin Neoplasms - chemically induced | Proto-Oncogene Proteins c-myc - metabolism | Mice, Knockout | Skin Neoplasms - metabolism | Keratinocytes - pathology | Animals | Tumor Suppressor Protein p53 | Keratinocytes - drug effects | Keratinocytes - metabolism | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins c-myc - deficiency | Skin Neoplasms - genetics | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Ubiquitin-Protein Ligases - deficiency | Mice | Proto-Oncogene Proteins c-myc - genetics | Cyclin-Dependent Kinase Inhibitor p15 - metabolism | Genes, ras | Ubiquitin-Protein Ligases - genetics | Oncogene Protein p21(ras) - genetics | Carcinogenesis | Ras genes | Analysis | Research Paper
Journal Article
Details
Digital rights
Loading Rights